The New York Times, April 23, 2021 (with Emily Anthes and Noah Weiland)
The Food and Drug Administration ended its recommended pause on the Johnson & Johnson Covid-19 vaccine on Friday and will add a warning to its label to note the potential risk of rare blood clots.
The decision, which clears the way for states to resume vaccinations, came after a panel of advisers to the Centers for Disease Control and Prevention voted to end the pause in a meeting on Friday.
The New York Times, April 16, 2021 (with Noah Weiland)
The White House on Friday announced an almost $2 billion plan for expanding and improving the nation’s ability to track coronavirus variants, an effort that public health experts have said is desperately needed to fight against variants that could drive another wave or potentially undermine the effectiveness of vaccines.
The New York Times, April 14, 2021 (with Denise Grady)
The pause in the use of Johnson & Johnson’s Covid-19 vaccine may continue for a week to 10 days, after expert advisers to the Centers for Disease Control and Prevention determined on Wednesday that they needed more time to assess a possible link to a rare but serious blood-clotting disorder.
The New York Times, April 13, 2021 (with Denise Grady)
On Tuesday morning, U.S. federal health regulators recommended a pause in the use of Johnson & Johnson’s Covid-19 vaccine while they investigated six reports of blood clots in women ages 18 to 48. One has died, and a second is hospitalized in critical condition.
Continue reading “J&J Vaccine and Blood Clots: The Risks, if Any, Are Very Low”
The New York Times, April 13, 2021 (with Noah Weiland and Sharon LaFraniere)
Injections of Johnson & Johnson’s coronavirus vaccine came to a sudden halt across the country on Tuesday after federal health agencies called for a pause in the vaccine’s use as they examine a rare blood-clotting disorder that emerged in six recipients.
Continue reading “Johnson & Johnson Vaccinations Paused After Rare Clotting Cases Emerge”